November 8th, 2011: Gene Expression Profile in Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, Jules Bordet Institute, Brussels, Belgium
New York University Langone Medical Center, New York, NY
Table of Contents
Clinical Case
0:02:18
Adjuvant! Online
0:02:53
Prognosis - 10 year survival
0:04:42
Gene expression profile in B.C. Plan of the talk
0:05:28
Gene prognostic signatures:
0:06:14
Recurrence score (Tamoxifen only)
0:07:00
Mammaprint (Untreated)
0:08:06
Gene prognostic signatures: Proliferation= driving force
0:08:45
Gene prognostic signatures: Informative for ER /HER2-BC
0:09:38
Gene prognostic signatures: Stage (T,N) still matters
0:10:11
Gene signatures: 1.Which women can be spared adjuvant chemotherapy?
0:11:16
Which women with LUMINAL phenotype BC benefit from chemo?
0:11:56
High RS ER BC patients benefit from chemo irrespectively of nodal burden
0:12:55
Gene signatures: 2. Which women with B.C. benefit from chemotherapy?
0:13:54
Clouds in the blue sky: the EBCTCG chemotherapy overview!
0:14:40
The current paradox
0:16:45
Mindact Trial Design
0:18:18
Patient registration and enrollment
0:20:41
Patient characteristics
0:21:33
Treatment decision outcome
0:22:01
Compliance with assigned treatment per enrollment
0:22:59
MINDACT TRIAL: Conclusions
0:23:12
The RASTER study
0:24:11
Low Risk: 158 pts without adjuvant systemic treatment
0:24:37
Pooled analysis of gene expression studies to predict neoadjuvant (taxanes and/or anthracyclines) chemotherapy response
0:26:55
Gene signatures: 2. Which women with B.C. benefit from chemotherapy?
0:27:48
Multigene signatures predicting chemotherapy efficacy
0:28:55
The 30-gene predictor captures molecular equivalents of clinical phenotype such ER and grade!
0:30:32
Multigene signatures predicting chemotherapy efficacy
0:31:31
Trial of Principle (TOP Trial)
0:31:44
TOP2A amplification predicts for pCR but not TOP2A mRNA and protein over-expression
0:32:43
The TOP2A signature
0:33:09
The TOP2A signature predicts pCR
0:33:16
Anthracycline-based score (the A-Score)
0:33:59
Validation of the A-Score in two independent studies
0:34:35
8q22 amplification and over-expression of LAPTM4B/YWHAZ is associated with de novo anthracycline-based chemotherapy resistance
0:36:20
Gene signatures: 3. Which chemotherapy regimen for which patient?
0:36:40
Red-out molecular pathways matters
0:38:05
Correlation of PIK3CA mutation with clinical outcome
0:38:57
PIK3CA Signature
0:40:10
Correlation of PIK3CA-GS with clinical outcome
0:40:36
Does PIK3CA-GS predict for response to PI3K pathway inhibitors?
0:43:20
The PIK3CA-GS is associated with anti-proliferative response to Everolimus
0:44:06
Evolution of molecular testing
0:45:31
No Description
 
  • Comments
  • Description
   
Sign up to Add Comment!
 
Characters Left :
  
    Brief Description
 
At the NYU Internal Medicine Grand Rounds Dr. Piccart-Gebhart presents on moving from prognostic to predictive gene signatures.
 
    Full Description
 
 
    Citation
 
 
    Abstract
 
 
    Introduction
 
 
    Results
    Discussions
 
 
    Material Methods
 
 
    References
 
 
 
 
Stats
 
Publish date Views Ref#
Nov 09, 2011 941 VA:11:08:6672:2011
 
Rating
   
 
Your rating: None
 
Embed Code
 
Files
 
 
 

Contact Us | Investors | About VeoMed | News | Help

Copyright ® VeoMed.com 2006-2007 All Rights Reserved    Privacy Policy | Terms of Use

Quick Links
Open Access
My Dashboard
Login
Signup